Background: Treatment based on nab-paclitaxel plus gemcitabine is one of the standard treatments for locally advanced or metastatic pancreatic adenocarcinoma. Not much information is available about its use in clinical practice. Looking for prognostic markers may aid in improving treatment plans for patients.
View Article and Find Full Text PDFAim: Obinutuzumab induces NK cell antibody-dependent cell-mediated cytotoxicity.
Objective: Investigate the effects on the human immune system after obinutuzumab monotherapy treatment in patients with chronic lymphocytic leukemia (CLL).
Method: To evaluate these effects, we analyzed the distribution of CD4 and CD8 T cells, B cells and NK cells in the peripheral blood of eight CLL patients who were treated with obinutuzumab in monotherapy.